- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Investors, drug/device developers share facts
Pittsburgh—Senior executives from some 50 biotechnology, pharmaceutical, and device firms examined the potential for combination drug/device therapies in a weekend conference showcasing the most promising advances.
Pittsburgh-Senior executives from some 50 biotechnology, pharmaceutical, and device firms examined the potential for combination drug/device therapies in a weekend conference showcasing the most promising advances.
The meeting, sponsored by AdvaMed, BIO, MedTech Insight, The Pittsburgh Life Sciences Greenhouse, and Windhover Information, explored the potentially "explosive" growth predicted for combination drug/device therapies. Representatives of venture capital firms and investment banks also attended the meeting to gather information on potential partnering opportunities.
Presenting companies included Light Sciences Corp., which discussed its progress on the development of its Litx System for the treatment of age-related macular degeneration and other diseases.
